Decoy receptors: A strategy to regulate inflammatory cytokines and chemokines

Trends in Immunology

Volumn 22, Issue 6, 2001, Pages 328-336

  Mantovani, Alberto ^a   Locati, Massimo ^b   Vecchi, Annunciata ^a   Sozzani, Silvano ^a   Allavena, Paola ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DECOY RECEPTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; LIGAND; OSTEOPROTEGERIN; RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

GENE EXPRESSION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; CHEMOKINES; CYTOKINES; HUMANS; INFLAMMATION; LIGANDS; MODELS, IMMUNOLOGICAL; MOLECULAR SEQUENCE DATA; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOKINE;

EID: 0034919056     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(01)01941-X     Document Type: Review

References (90)

1. On nerve endings and on special excitable substances in cells
2. Chemotherapeutics: Scientific principles, methods and results
3. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4
4. The type II 'decoy' receptor: Novel regulatory pathway for interleukin-1
5. Soluble cytokine receptors: Their roles in immunoregulation, disease and therapy
6. Soluble cytokine receptors
7. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment
8. Anti-cytokine therapy for rheumatoid arthritis
9. The IL-1 receptor/toll-like receptor superfamily: Crucial receptors for inflammation and host defense
10. Binding of IL-1α, IL-1β and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids
11. Soluble type II interleukin-1 (IL-1) receptor binds and blocks processing of IL-1β precursor and loses affinity for IL-1 receptor antagonist
12. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor
13. The type II 'receptor' as a decoy target for IL-1 in polymorphonuclear leukocytes: Characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor
14. Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: A surface 'receptor' with anti-interleukin-1 function
15. Transfected type II interleukin-1 receptor impairs responsiveness of human keratinocytes to interleukin-1
16. Gene transfer-mediated expression of physiological numbers of the type II decoy receptor in a myelomonocytic cellular context dampens the response to interleukin-1
17. The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis
18. Keratinocyte expression of the type 2 interleukin-1 receptor mediates local and specific inhibition of interleukin-1-mediated inflammation
19. Viral mechanisms of immune evasion
20. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: A novel mechanism of regulation of IL-1 responsiveness
21. Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor
22. Regulated expression and release of the interleukin-1 decoy receptor in human mononuclear phagocytes
23. Interleukin-13 induces expression and release of the interleukin-1 decoy receptor in human polymorphonuclear cells
24. Interleukin-4 ameliorates experimental glomerulonephritis and up-regulates glomerular gene expression of IL-1 decoy receptor
25. The combination of endotoxin and dexamethasone induces type II interleukin-1 receptor (IL-1RII) in monocytes: A comparison to interleukin-1β (IL-1β) and interleukin-1 receptor antagonist (IL-1ra)
26. Effects of dexamethasone treatment on IL-1 receptor mRNA levels in vivo
27. IFN-γ and IL-10 inhibit induction of IL-1 receptor type I and type II gene expression by IL-4 and IL-13 in human monocytes
28. Aspirin-induced increases in soluble IL-1 receptor type II concentrations in vitro and in vivo
29. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts
30. Divergent effects of LPS on expression of IL-1 receptor family members in mononuclear phagocytes in vitro and in vivo
31. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein
32. Inducible expression of type 2 IL-1 receptors by cultured human keratinocytes. Implication for IL-1-mediated processes in epidermis
33. Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA
34. Role of the metalloproteases in the release of the IL-1 type II decoy receptor
35. Selectivity release of the type II decoy IL-1 receptor
36. Chemoattractants induce rapid release of the interleukin-1 type II decoy receptor in human polymorphonuclear cells
37. TNF-α, unlike other pro- and anti-inflammatory cytokines, induces rapid release of the IL-1 type II decoy receptor in human myelomonocytic cells
38. Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome
39. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia
40. The pattern of interleukin-1β (IL-1β) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections
41. Anti-inflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10 and IL-13
42. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy
43. Enhancement of anti-inflammatory mediator soluble interleukin-1 receptor II (sIL-1RII) during treatment of exacerbation of chronic obstructive pulmonary disease
44. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis
45. Reversal of autocrine and paracrine effects of interleukin-1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention
46. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response
47. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response
48. Osteoprotegerin ligand: A regulator of immune responses and bone physiology
49. Death receptors: Signaling and modulation
50. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
51. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
52. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
53. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
54. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
55. Bone cancer gain without the pain
56. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
57. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
58. Steering anti-cancer drugs away from the TRAIL
59. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
60. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity
61. A membrane-bound Fas decoy receptor expressed by human thymocytes
62. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
63. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis
64. The chemokine system: Redundancy for robust outputs
65. Chemokines
66. The interleukin-8-receptor family-from chemokines to malaria
67. From malaria to chemokine receptor: The emerging physiologic role of the Duffy blood group antigen
68. International union of pharmacology. XXII. Nomenclature for chemokine receptors
69. Postcapillary venule endothelial cells in kidney express a multispecific chemokine receptor that is structurally and functionally identical to the erythroid isoform, which is the Duffy blood group antigen
70. The Duffy antigen receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor
71. -) phenotype
72. Cloning, expression and chromosomal mapping of a novel human CC-chemokine receptor (CCR10) that displays high-affinity binding for MCP-1 and MCP-3
73. Cloning and characterization of a novel murine β chemokine receptor, D6-comparison to three other related macrophage inflammatory protein-1α receptors, CCR-1, CCR-3 and CCR-5
74. Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines
75. Deletion of the murine Duffy gene (Dfy) reveals that the Duffy receptor is functionally redundant
76. HIV-1 entry and macrophage inflammatory protein-1β-mediated signaling are independent functions of the chemokine receptor CCR5
77. Uncoupling of inflammatory chemokine receptors by IL-10: Generation of functional decoys
78. B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state and B-cell receptor engagement
79. CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3α
80. Receptor expression and responsiveness of human dendritic cells to a defined set of CC- and CXC-chemokines
81. Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes
82. Central role for G protein coupled phosphoinositide 3-kinase γ in inflammation
83. The chemokine receptor switch paradigm and dendritic cell migration: Its significance in tumor tissues
84. Viral exploitation and subversion of the immune system through chemokine mimicry
85. Inflammation and cancer: Back to Virchow?
86. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: Withdrawal of chemokines from the environment of cytomegalovirus-infected cells
87. Wnt signaling and the activation of myogenesis in mammals
88. Wnt signaling is required for thymocyte development and activates Tcf-1 mediated transcription
89. Cloning and characterization of interleukin-22 binding protein (IL-22BP), a natural antagonist of IL-TIF/IL-22
90. Identification, cloning and characterization of a novel soluble receptor which binds IL-22 and neutralizes its activity